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Material and Methods: Our cohort includes 15 pts (6 girls, 9 
boys) treated with RT for HL, in age 6-25 years (median 17) 
at the RT, from 2008 to 2013. The 15 pts are representative 
of different RT target volumes (e.g. bilateral neck, ipsilateral 
neck, mediastinum, mantel-field, lombo-aortic and spleen, 
inverted Y, inguinal field, or a combination of them). We 
calculated the excess absolute of risk (EAR) end the 
cumulative risk of “all solid” and “single organ” SMN: mouth 
and pharynx, parotids glands, thyroid, lung, stomach, small 
intestine, colon, liver, cervix, bladder, brain and spinal cord, 
skin, female breast, bone and soft tissue. Every HT plan has 
been compared with 3D-CRT plan, both for EAR, cumulative 
risk and target coverage. 
 
 
Results: The risk of SMN solids is high, for both techniques, 
for breast, lung, thyroid, skin and colon. Some HT treatments 
may lead to increased risk of SMN solid than 3D-CRT plans, 
depending on the patient's age at exposure, on the specific 
organ volume or target volume and on the dose-response of 
each site. All the HT plans have the best conformation to the 
target and the greatest homogeneity of the dose to it 
delivered (best conformation number and homogeneity 
index). 
 
 
In this table: EAR (/10000 pts-year) at agea 60 in HT and 3D-
CRT for all pts (1-15: pink=girl, cyan=boy); DT=target dose in 
cGy, agex= age at pt's radiation treatment, n= number of RT 
fractions.Green=max value for each line.Red= statistically 
significant EAR ratio with EAR HT>EAR 3D-CRT; blue= 
statistically significant EAR ratio with EAR 3D-CRT> EAR HT 
 
Conclusion: Even if HT increases the target coverage in all 
pts, it could increase the incidence of SMN compared with 
3D-CRT for long-term survivors, depending on single specific 
target, target volume and pts age. However, EAR estimates 
are affected by large uncertainties and more works should be 
performed to better understand the risk of SMN with modern 
RT techniques after a childhood cancer. 
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A central independent quality assurance (QA) process is 
acknowledged as an essential component of current 
radiotherapy clinical trials. QA processes are implemented 
both pre accrual and during accrual. The former ensures 
centres have the equipment, expertise and ability to comply 
with trial protocol requirements and that they are able to 
deliver treatment accurately and consistently. During accrual 
processes assure continued compliance and consistency of 
treatment delivery both within individual centres and across 
all recruiting centres throughout the trial. The key process 
areas in QA activity are: 
Target volume and organ at risk outlining 
Treatment planning and optimisation 
Treatment delivery and verification 
Dosimetry Audit 
This talk will focus on the following main themes expanding 
on the processes involved and providing evidence and 
examples from individual trial QA programmes. 
The implementation of clinical trial QA: Appropriate QA tasks 
to include questionnaires, process documents through review 
of example patient cases to dosimetry audit site visits, are 
assigned on an individual trial basis. The level of QA required 
will vary according to the complexity and novelty of the 
radiotherapy technique. 
Defining standards: It is well recognised that target volume 
and OAR delineation and treatment planning and optimisation 
may be variable and open to individual interpretation. 
Through multi professional trial workshops, provision of 
delineation guidelines and setting of dose-volume 
constraints, consensus benchmark standards can be defined. 
Assessment against a benchmark: Conformity metrics and 
pre-defined mandatory and optimal dose constraints can be 
used to review against consensus standards to highlight 
potential protocol variations. Historically this review has 
been retrospective; however increasing use of prospective 
evaluation with constructive feedback can allow correction of 
protocol variations before treatment is delivered.  
Verification of treatment delivery: Dosimetry audit in the 
form of a postal or site visit serves to provide an independent 
assessment of dose delivered and directly compares 
individual centres. Recently, resulting from advances in 
image guidance, adaptive radiotherapy has been introduced 
in the clinical trial setting, introducing new challenges in 
assessment of plan selection competency and compliance.  
As more advanced technology is introduced in the clinical 
trial setting, QA activities must continually evolve to provide 
a safe framework for implementation of technical 
radiotherapy. Increased participation in clinical trials 
demands a streamlined approach to QA to reduce workload, 
improve efficiency and facilitate opening centres for 
recruitment earlier. Participation in a comprehensive QA 
programme not only accredits the centre for recruitment but 
also benefits the general standard of RT delivered. 
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Radiotherapy (RT) planning and delivery for cancer 
management has substantially evolved over the last three 
decades with lately the introduction of intensity modulated 
RT, image-guided RT and stereotactic ablative RT to name a 
few techniques. The evaluation of these high precision 
delivery techniques in routine care and in clinical trials alike 
are error prone. They thus do require optimal RT quality 
(RTQA) assurance programs which aim at defining the range 
of acceptable variations and importantly developing 
mechanisms of action for correction and prevention of 
potential variations. RTQA outside a clinical trial is defined 
by all processes that ensure consistency of the dose 
prescription and the safe delivery of that prescription with 
regard to dose to the target and critical structures, 
minimization of the exposure of the RT personnel. In the 
framework of clinical trials assessing the efficacy of RT with 
or without a combined modality, RTQA is also necessary to 
avoid the corruption of the study-endpoint, as RT variations 
from study protocol decrease the therapeutic effectiveness 
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and/or increase the likelihood of radiation-induced toxicities. 
Prospective trials have shown that RTQA variations have a 
significant impact on the primary study end-point and could 
bias the analysis of the trial results[6]. A large prospective 
phase III (i.e. TROG 02.02) trial showed indisputably that 
poor radiotherapy resulted in suboptimal patient’s outcomes. 
Moreover, the impact of poor quality radiotherapy delivery 
exceeded greatly the benefit of chemotherapy, thus biasing 
the primary end-point of this study. This large Australian trial 
provided a contemporary benchmark that future studies will 
need to exceed. Other specific consideration for RTQA in 
trials includes, but is not limited to, education of the 
accruing sites in RT-trial guidelines, promotion of consistency 
between centers and estimation of inter-patient and inter-
institutional variations. Additionally, global cooperation is 
essential in the environment of common and rare cancers 
alike, in order to be able to create sufficiently large patient 
data sets within a reasonable recruitment period. This 
cooperation is not without issues and recently the need to 
have harmonized RTQA procedures has been strongly 
advocated by the Global Harmonisation Group. Ensuring RT 
compliance with protocol guidelines involves however 
gradually more resources-intensive procedures which are also 
labor intensive and are not cost-neutral. This will 
consequentially have a significant impact on the overall study 
budget. There are suggestion that QA programs are however 
cost-effective. This financial investment is of paramount 
importance, as non-adherence to protocol-specified RT 
requirements in prospective trials is very frequent. The 
European Organisation for the Research and Treatment of 
Cancer (EORTC) Radiation Oncology Group started to 
implement RTQA strategies in the 1980s, including on how to 
write a protocol for RT trials, defining RTQA procedures (such 
as benchmark case, dummy run and complex treatment 
dosimetry checks), assuring prospective individual case 
review feasibility and implementing an electronic data-
exchange platform.  
Keywords: Quality assurance, RTQA, prospective trial, 
patient’s outcome, toxicity  
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A trial protocol with clearly established delineation 
guidelines and dose-volume parameters is key to all RTQA. 
Acceptable and unacceptable variations thereof should be 
defined before the trial starts as these are the standards to 
which all RTQA data collected will be compared. The 
experience so far has been addressed by the previous two 
speakers. Dr. Miles presented the RTQA procedures in clinical 
trials, differentiating between pre-accrual and during accrual 
tasks. Thereafter, Dr. Weber clearly showed that non 
adherence to protocol-specified RT requirements is 
associated with reduced survival, local control and 
potentially increased toxicity. Thus, it can be concluded that 
clinical trial groups have established RTQA procedures and 
conformance to these procedures strengthen the trial results.  
In this talk the remaining issues that need to be solved will 
be addressed. These issues can be separated in:  
1. How can we further optimising the current RTQA 
2. How should we include new imaging and treatment 
modalities in our RTQA program?  
The first part of the talk will address several initiatives to 
further optimise current RTQA procedures. As we have 
learned from past RTQA experience, currently the individual 
case reviews (ICRs) are the most common source of variations 
from trial protocols. ICR variation is also the most important 
RTQA factor affecting trial outcome. Thus, a transition is 
needed from retrospective ICRs to timely, full prospective 
ICRs. Also, with the further advancement of tailored 
treatments for small subgroups of patients there is a growing 
need for intergroup trials to increase the accrual rates when 
conducting trials for such patient groups. These changes 
place new requirements on multiple parts in the RTQA 
procedure:  
- Standardisation of RTQA across various trial groups. The 
Global Harmonisation Group initiative. 
- Standardisation of protocol requirements with clear 
definitions of acceptable and unacceptable variations. 
- Standardisation of OAR and target naming conventions. 
- Automated upload of RTQA data from institutions to the 
RTQA review organisation, including anonymisation software, 
use of Dicom standards. 
- Metrics and software tools to automatically evaluate image 
quality, delineations and treatment plans.  
The second part of the talk will address the ideas of including 
new diagnostic, treatment and evaluation modalities and 
techniques in RTQA programs. Examples will be shown of 
RTQA trial procedures for breathing correlated 4D-CT, 4D 
PET-CT, MRI and CBCT currently in use or under 
development.  
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Purpose or Objective: There is conclusive evidence that 
radiotherapy (RT) can initiate an immune response. 
Previously, we have shown that addition of L19-IL2 to RT was 
able to increase the immune response and that this 
combination therapy resulted in a long-lasting synergistic 
anti-tumor effect. Here we hypothesize that tumor cells 
outside the radiation field will also be eliminated by this 
combination treatment (abscopal effect) and that tumors 
cannot be formed again after re-challenging cured animals 
(memory effect). 
 
Material and Methods: Immunocompetent Balb/c mice were 
subcutaneously injected with syngeneic colorectal C51 cells 
in both flanks at different days. Primary tumors were 
irradiated upon a volume of 200 mm³ (15Gy or 5x2Gy) 
followed by PBS or L19-IL2 administration and the growth of 
the secondary non-irradiated tumors was monitored. Cured 
mice were reinjected after 150 days with C51 tumor cells and 
tumor uptake was assessed. Several immunological 
parameters in blood, tumors, lymph nodes and spleens were 
investigated in both experiments. 
 
Results: RT+L19-IL2 was able to cure 100% of primary tumors 
and was associated with an increased percentage of CD8+ T 
cells inside these irradiated tumors. When a single RT dose of 
15Gy was combined with L19-IL2, 20% of the non-irradiated 
secondary tumors were cured. Interestingly, the non-
irradiated tumors of mice treated with 15Gy+L19-IL2 showed 
a significant (p<0.01) increased percentage of CD4+ T cells 
compared to irradiated tumors. Fractionated radiotherapy 
combined with L19-IL2 caused a significant (p<0.01) growth 
delay in the non-irradiated tumors, however no secondary 
tumors were cured. Immunological analysis revealed an 
increase in PD-1 expression on T cells infiltrating these 
tumors, suggesting a more regulatory phenotype after 
fractionated radiotherapy compared with one single RT dose. 
New C51 tumors were not able to form in cured mice whereas 
100% of the age-matched control mice formed tumors that 
reached established end-points within 17 days. Splenic T cells 
of these cured mice were associated with a high expression 
of CD127. 
 
Conclusion: Our data show that RT+L19-IL2 causes anti-tumor 
immune effects outside the radiation field and this effect is 
associated with an increase of CD4+ T cells. Cured mice are 
